A Canadian multicentre prospective study on the effects of an oral contraceptive containing 3 mg drospirenone and 30 microg ethinyl oestradiol on somatic and psychological symptoms related to water retention and on body weight.

@article{Endrikat2007ACM,
  title={A Canadian multicentre prospective study on the effects of an oral contraceptive containing 3 mg drospirenone and 30 microg ethinyl oestradiol on somatic and psychological symptoms related to water retention and on body weight.},
  author={Jan Endrikat and Mirella Sandri and Christoph Gerlinger and Alexander Ruebig and Werner Schmidt and Michel Fortier},
  journal={The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception},
  year={2007},
  volume={12 3},
  pages={
          220-8
        }
}
OBJECTIVES To evaluate the effects of an oral contraceptive containing 3 mg drospirenone (DRSP) and 30 microg ethinyl oestradiol (EE) on somatic and psychological symptoms related to water retention, and on body weight. METHODS This prospective study was performed in 26 centres in Canada over six treatment cycles. The first primary efficacy variable was the individual change in the water retention score of the Moos Menstrual Distress Questionnaire (MDQ) from baseline to the final examination… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-8 OF 8 CITATIONS

Effects of low dose oral contraceptive pill containing drospirenone/ethinylestradiol in patients with endometrioma.

  • European journal of obstetrics, gynecology, and reproductive biology
  • 2015
VIEW 1 EXCERPT
CITES BACKGROUND